窪蹋勛圖厙

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 窪蹋勛圖厙 News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Dec 22 2015

Full Issue

Biotech Company Reports Promising Results In 'Kick And Kill' HIV Treatment

The firm says its method has reduced latent HIV in 17 patients by an average of 40 percent. In other news, public health officials want to know why a drug that has proven effective at preventing HIV is not being used.

A small Norwegian biotechnology firm said Monday it had the first evidence of real promise in a new approach widely considered to be a potential cure for HIV, prompting both cautious optimism and skepticism from experts. One approach thought to be a possible route to a cure, known as kick and kill or shock and kill, seeks to expose these latent HIV-infected cells so they can be cleared away by the immune system. Bionor Pharma ASA said its method had reduced the size of the latent HIV reservoir by an average of 40% across 17 patients. (Roland, 12/21)

Public-health officials are pushing for much wider use of a drug that has proved effective at preventing HIV infection. PrEP, or preexposure prophylaxis, is a daily medication that people at high risk for HIV can take to protect against acquiring the virus. Still, fewer than 22,000 people are estimated to have taken PrEP for prevention. (Reddy, 12/21)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, June 8
  • Friday, June 5
  • Thursday, June 4
  • Wednesday, June 3
  • Tuesday, June 2
  • Monday, June 1
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 窪蹋勛圖厙
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

穢 2026 KFF